At a glance
- Originator Pfizer
- Class Antibacterials; Ketolides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Respiratory tract infections
Most Recent Events
- 26 Sep 2000 Preclinical development for Respiratory tract infections in USA (Unknown route)
- 26 Sep 2000 New profile